ERBB2 and breast carcinoma: Phase III trials have demonstrated that CDK4/6 inhibitors offer prolonged progression-free (PFS) and overall survival (OS) in patients with metastatic HR-positive, HER2-negative breast cancer compared with endocrine therapy [11].